Cargando…
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells
Breast cancer is commonly treated with anti-estrogens or aromatase inhibitors, but resistant disease eventually develops and new therapies for such resistance are of great interest. We have previously isolated several tamoxifen-resistant variant sub-lines of the MCF-7 breast cancer cell line and pro...
Autores principales: | Leung, Euphemia, Rewcastle, Gordon W., Joseph, Wayne R., Rosengren, Rhonda J., Larsen, Lesley, Baguley, Bruce C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484282/ https://www.ncbi.nlm.nih.gov/pubmed/22105790 http://dx.doi.org/10.1007/s10637-011-9768-4 |
Ejemplares similares
-
Evidence for the Existence of Triple-Negative Variants in the MCF-7 Breast Cancer Cell Population
por: Leung, Euphemia, et al.
Publicado: (2014) -
Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines
por: Leung, Euphemia Y., et al.
Publicado: (2015) -
Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines
por: Leung, Euphemia Y., et al.
Publicado: (2014) -
Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs
por: Leung, Euphemia Yee, et al.
Publicado: (2014) -
CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)